BIO vs RVTY
BIO: A multinational life science and clinical diagnostics company providing research tools, diagnostic test systems, and consumables to laboratories and biopharmaceutical manufacturers worldwide. RVTY: Revvity is a leading health science technology company providing integrated workflows and reagents spanning drug discovery, development, and diagnostic applications across life sciences and diagnostics markets.
Side-by-side fundamentals
| Metric | BIO | RVTY | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $316.41 | $108.07 | |
| Market cap as of 2026-07-30 | $8.8B | $12.1B | |
| P/E as of 2026-07-30 | 52.37 | 51.93 | RVTY lower |
| PEG as of 2026-07-30 | n/a | 5.11 | |
| Net margin as of 2026-07-30 | +6.5% | +8.3% | RVTY higher |
| Gross margin as of 2026-07-30 | +51.8% | +54.3% | RVTY higher |
| Operating margin as of 2026-07-30 | +2.0% | +12.4% | RVTY higher |
| ROE as of 2026-07-30 | +2.4% | +3.3% | RVTY higher |
| ROA as of 2026-07-30 | +1.7% | +2.0% | RVTY higher |
| Debt / equity as of 2026-07-30 | 0.18 | 0.45 | BIO lower |
| Revenue growth (YoY) as of 2026-07-30 | +1.9% | +4.8% | RVTY higher |
| Revenue CAGR (3y) SEC XBRL | -2.7% | -9.3% | BIO higher |
| Dividend yield as of 2026-07-30 | n/a | +0.3% | |
| Dividend streak (yrs) SEC XBRL | n/a | 3 | |
| Beta as of 2026-07-30 | 1.02 | 1.07 | |
| 1-year return as of 2026-07-27 close | +19.8% | +4.2% | BIO higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.